Gene Editing Therapeutics Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GENE EDITING THERAPEUTICS MARKET BY DELIVERY METHOD

1. 5.1. Introduction

2. 5.2. Ex Vivo Gene Editing

3. 5.3. In Vivo Gene Editing

6. GENE EDITING THERAPEUTICS MARKET BY TECHNOLOGY

1. 6.1. Introduction

2. 6.2. CRISPR-Cas Systems

3. 6.3. TALENs (Transcription Activator-Like Effector Nucleases)

4. 6.4. Zinc Finger Nucleases (ZFNs)

5. 6.5. Base Editing

6. 6.6. Prime Editing

7. 6.7. Others

7. GENE EDITING THERAPEUTICS MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Oncology

3. 7.3. Genetic Disorders

4. 7.4. Cardiovascular Diseases

5. 7.5. Neurological Disorders

6. 7.6. Infectious Diseases

7. 7.7. Metabolic Disorders

8. 7.8. Others

8. GENE EDITING THERAPEUTICS MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. CRISPR Therapeutics AG

2. 10.2. Intellia Therapeutics, Inc.

3. 10.3. Editas Medicine, Inc.

4. 10.4. Beam Therapeutics Inc.

5. 10.5. Sangamo Therapeutics, Inc.

6. 10.6. Precision BioSciences, Inc.

7. 10.7. Cellectis S.A.

8. 10.8. Caribou Biosciences, Inc.

9. 10.9. Verve Therapeutics, Inc.

10. 10.10. Prime Medicine, Inc.

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations